MedDataX Logo

Prevention Of Nephrotoxicity Following Bone Marrow Transplantation Using Urodilatin and Mannitol

NCT00390624 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2008-06-03

No results posted yet for this study

Summary

The purpose of the study is to combine Urodilatin (ANP analogue), which will increase glomerular filtration rate (GFR), and mannitol, which will increase the rate of urinary flow and solute excretion. We intend to treat twenty consecutive allogeneic bone marrow transplant patients in a phase II study comparing results with historical controls.

We hypothesize that the incidence of renal dysfunction, ARF and thus mortality in allogeneic bone marrow transplantation can be significantly reduced by the use of protective agents Urodilatin and mannitol. We feel that this combination is best administered prior to and during the first two weeks of treatment when patients encounter immunosuppressive agents and the onset of early transplantation complications.

Conditions

  • Renal Dysfunction
  • Acute Renal Failure
  • Mortality

Interventions

DRUG

URODILATIN (ULARITIDE, ATRIAL NATRIURETIC PEPTIDE)

DRUG

MANNITOL

Sponsors & Collaborators

  • University of Colorado, Denver

    collaborator OTHER

  • Rocky Mountain Cancer Centers

    lead OTHER

Principal Investigators

  • Chirag R Parikh, MD, PhD · Yale School of Medicine (Nephrology)

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Primary Completion
2006-12-31
Completion
2006-12-31

Countries

  • United States

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00390624 on ClinicalTrials.gov